Systemic medication as a safety variable in dermatologic laser and energy-based device procedures: a practical risk-stratification framework

Abstract

Dermatologic laser and energy-based device procedures are increasingly performed in patients receiving systemic medication. Traditional pre-procedure screening often treats selected drugs as binary contraindications, although the relevance of medication exposure depends on device type, wavelength, pulse duration, cooling, treatment endpoint, tissue depth, epidermal barrier disruption, treatment area, skin phenotype, and follow-up capacity. This practical review proposes a structured framework for incorporating systemic medication into laser and energy-based device safety assessment. PubMed-based evidence mapping was organized by medication class and procedure category. Evidence was graded pragmatically as direct laser or energy-based device evidence, indirect procedural evidence, pharmacologic or biologic plausibility, or absent evidence. The strongest medication-specific laser evidence concerns isotretinoin, where historical blanket delays have been reconsidered for many low-injury and fractional procedures. Antithrombotic agents and Bruton tyrosine kinase inhibitors primarily modify bleeding and purpura risk, with most evidence extrapolated from dermatologic surgery. Direct laser-specific evidence remains sparse for biologics, Janus kinase inhibitors, conventional immunosuppressants, systemic corticosteroids, targeted oncologic therapies, and immune checkpoint inhibitors. Photosensitizing and pigment-altering drugs are most relevant for intense pulsed light, photodynamic therapy, pigment lasers, and darker phototypes. Systemic medication should be considered a procedure-dependent safety variable rather than an automatic contraindication. The proposed framework integrates medication class, procedure injury profile, patient phenotype, and evidence grade to support individualized risk assessment and shared decision-making.